Sudarshan Pharma Industries Ltd

Sudarshan Pharma Industries Ltd has announced the closure of its trading window from July 1, 2026, until 48 hours after the declaration of financial results for the quarter ended June 30, 2026. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, aimed at preventing insider trading during the period leading up to and immediately following the announcement of financial performance. The company has provided its BSE Scrip Code (543828), Trading Symbol (SUDARSHAN), and ISIN (INE00TV01023) for reference.

Sudarshan Pharma Industries Ltd announced the cancellation of its Board of Directors meeting that was scheduled for Thursday, June 18, 2026. The cancellation is attributed to unavoidable reasons. The company has not provided a new date for the rescheduled meeting.

Sudarshan Pharma Industries Ltd has announced that its Board of Directors will convene on June 18, 2026. The primary agenda item is to consider and approve a proposal for raising funds. The company may utilize instruments such as equity shares, convertible securities, warrants, or debt securities through methods like private placement, preferential issue, or qualified institutions placement. The board will also approve necessary ancillary actions for the fund-raising exercise, subject to regulatory approvals.

Sudarshan Pharma Industries Ltd announced the allotment of 90,00,000 equity shares of face value Re. 1 each at an issue price of Rs. 16.983 per share. This allotment is a consequence of the conversion of 9,00,000 warrants, previously issued on a preferential basis to the Promoter Category. The company received the balance amount aggregating to Rs. 11,46,35,250/- for this conversion. The issued and paid-up capital of the company has increased to Rs. 24,96,58,870/-, consisting of 24,96,58,870 equity shares. The newly allotted shares will rank pari-passu with existing equity shares.

Sudarshan Pharma Industries Ltd has announced the postponement of its Warrants Committee meeting, originally scheduled for June 11, 2026. The meeting will now take place on June 12, 2026. The agenda for the meeting includes the consideration and approval of the conversion of warrants and the subsequent allotment of equity shares.

Sudarshan Pharma Industries Ltd has announced the incorporation of Sudarshan Industries Inc. as a wholly-owned subsidiary in the United States of America. This new entity, Sudarshan USA, aims to expand the company's customer base within the US market. The subsidiary will engage in the trade of pharmaceuticals, healthcare products, and related chemicals. The incorporation marks a strategic step for Sudarshan Pharma to enhance its global presence and market reach.

Sudarshan Pharma Industries Ltd has announced a meeting of its Warrants Committee scheduled for Thursday, June 11, 2026. The primary agenda item for this meeting is to discuss and approve the conversion of warrants and the subsequent allotment of equity shares. This action is expected to impact the company's equity structure.

Sudarshan Pharma Industries Ltd has filed a disclosure under Regulation 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This filing pertains to the intimation of the release of a pledge on shares. The company has provided the necessary details regarding this pledge release to the stock exchange.

Sudarshan Pharma Industries Ltd has resubmitted its audited standalone financial results for the half-year and financial year ended March 31, 2026. This follows an earlier communication regarding discrepancies in the previously submitted financial results for the same period. The company has adopted Indian Accounting Standards (Ind AS) voluntarily from April 1, 2025. The financial statements have been reviewed by the Audit Committee and approved by the Board of Directors, with the statutory auditors issuing an unmodified review opinion. The company is engaged in manufacturing APIs, jobwork, and trading in chemicals and solvents, operating in a single reportable segment.

Sudarshan Pharma Industries Ltd's board approved the migration of its equity shares from the SME platform of BSE to the Main Board of BSE and NSE, subject to shareholder approval. They also approved the application for listing/trading on the Main Board of NSE. A postal ballot notice was approved to seek member approval for the migration. NSDL was appointed for remote e-voting, and Mr. Vishal Manseta was appointed as the scrutinizer for the postal ballot process.